dc.contributor.author | Erice, Alejo | |
dc.contributor.author | Varillas Delgado, David | |
dc.contributor.author | Caballero, Cristina | |
dc.date.accessioned | 2022-02-14T09:14:44Z | |
dc.date.available | 2022-02-14T09:14:44Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1198-743X | spa |
dc.identifier.uri | http://hdl.handle.net/10641/2795 | |
dc.description.abstract | Objective
To assess the antibody response in non-immunocompromised adults after two doses of BNT162b2.
Methods
Prospective, single-centre observational study in non-immunocompromised adults aged 18 years or more who received two doses of BNT162b2. The study contemplates analyses of serum samples collected 1.5, 3, 6, 9 and 12 months after the second dose of BNT162b2; results of the 1.5- and 3-month time-points are presented in this report. Antibodies against the receptor binding domain of the S1 subunit of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (anti-RBD antibodies) were measured using a commercial quantitative immunoassay. A threshold of 4160 AU/mL (corresponding to an ID50 of 1:250) was used as surrogate marker for serum neutralizing activity.
Results
Of 273 hospital workers who received two doses of BNT162b2, 260 (95%) agreed to participate in the study; 2/260 (0.8%) were excluded because of immunocompromised conditions. At the time of this report, 230/258 (89%) participants (mean age 46.0 years (SD 11.4 years); 143/230 (62%) female; 87/230 (38%) male) had completed 3 months of follow up after the second dose of BNT162b2. Thirty-six (16%) of the 230 had documented mild SARS-CoV-2 infection before receiving the first dose of BNT162b2. Median (interquartile range (IQR)) anti-RBD titres 1.5 months after vaccination were 9356 (5844–16 876) AU/mL; 3 months after vaccination, median anti-RBD titres had declined to 3952 (2190–8561) AU/mL (p < 0.001). Of 199/230 (86.5%) participants who had anti-RBD titres above 4160 AU/mL 1.5 months after the second dose of BNT162b2, only 95/230 (41%) maintained anti-RBD titres above this level 3 months after vaccination (p < 0.001).
Conclusions
The decline of anti-RBD antibodies 3 months after the second dose of BNT162b2 is of concern because it raises the possibility of a short-lived humoral immunity after vaccination. Booster doses of BNT162b2 might be required to maintain high titres of anti-RBD antibodies over time. | spa |
dc.language.iso | eng | spa |
dc.publisher | Clinical Microbiology and Infection | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | COVID-19 | spa |
dc.subject | Vaccines | spa |
dc.subject | Immunogenicity | spa |
dc.subject | SARS-CoV-2 | spa |
dc.title | Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | SMUR | spa |
dc.rights.accessRights | open access | spa |
dc.description.extent | 161 KB | spa |
dc.identifier.doi | 10.1016/j.cmi.2021.08.023 | spa |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/abs/pii/S1198743X21004857?via%3Dihub | spa |